Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
Masatoshi Kudo, Yusuke Kawamura, Kiyoshi Hasegawa, et al.
Liver Cancer (2021) Vol. 10, Iss. 3, pp. 181-223
Open Access | Times Cited: 493

Showing 26-50 of 493 citing articles:

Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma
Bin‐Yan Zhong, Zhi‐Cheng Jin, Jian-Jia Chen, et al.
Journal of Clinical and Translational Hepatology (2022) Vol. 000, Iss. 000, pp. 000-000
Open Access | Times Cited: 53
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
Thomas Yau, Vittorina Zagonel, Armando Santoro, et al.
Journal of Clinical Oncology (2022) Vol. 41, Iss. 9, pp. 1747-1757
Open Access | Times Cited: 45
Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma
Kazuki Maesaka, Ryotaro Sakamori, Ryoko Yamada, et al.
Hepatology Research (2022) Vol. 52, Iss. 7, pp. 630-640
Closed Access | Times Cited: 44
Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis
Yizhen Fu, Wei Peng, Weixiang Zhang, et al.
Journal of Gastroenterology (2023) Vol. 58, Iss. 4, pp. 413-424
Closed Access | Times Cited: 41
Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison
Yuri Cho, Bo Hyun Kim, Joong‐Won Park
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 252-262
Open Access | Times Cited: 41
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 3, pp. 593-604
Open Access | Times Cited: 36
The Performance of GALAD Score for Diagnosing Hepatocellular Carcinoma in Patients with Chronic Liver Diseases: A Systematic Review and Meta-Analysis
Ming‐Cheng Guan, Shiyu Zhang, Qian Ding, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 3, pp. 949-949
Open Access | Times Cited: 28
Treatment Strategy for Intermediate-Stage Hepatocellular Carcinoma: Transarterial Chemoembolization, Systemic Therapy, and Conversion Therapy
Takeshi Hatanaka, Yutaka Yata, Atsushi Naganuma, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1798-1798
Open Access | Times Cited: 28
Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations
Ming Zhao, Zhi Guo, Yinghua Zou, et al.
Hepatology International (2023) Vol. 18, Iss. 1, pp. 4-31
Closed Access | Times Cited: 26
Correlation and efficacy of TACE combined with lenvatinib plus PD‐1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features
Xinhua Zou, Qingyu Xu, Ran You, et al.
Cancer Medicine (2023) Vol. 12, Iss. 10, pp. 11315-11333
Open Access | Times Cited: 24
Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD
Masafumi Ikeda, Tatsuya Yamashita, Sadahisa Ogasawara, et al.
Liver Cancer (2023) Vol. 13, Iss. 2, pp. 193-202
Open Access | Times Cited: 24
Hepatic arterial infusion chemotherapy combined with lenvatinib and PD‐1 inhibitors versus lenvatinib and PD‐1 inhibitors for HCC refractory to TACE
Lingfeng Diao, Chendong Wang, Ran You, et al.
Journal of Gastroenterology and Hepatology (2024) Vol. 39, Iss. 4, pp. 746-753
Closed Access | Times Cited: 11
Hepatic Resection for Hepatocellular Carcinoma
Parissa Tabrizian, Adriana Pero, Myron Schwartz
Clinics in Liver Disease (2024) Vol. 29, Iss. 1, pp. 59-72
Closed Access | Times Cited: 11
Molecular mechanisms of TACE refractoriness: Directions for improvement of the TACE procedure
Jiahao Li, Yingnan Liu, Ruipeng Zheng, et al.
Life Sciences (2024) Vol. 342, pp. 122540-122540
Open Access | Times Cited: 10
Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study
Machiko Kai, Hayato Hikita, Maesaka Kazuki, et al.
PLoS ONE (2024) Vol. 19, Iss. 1, pp. e0294590-e0294590
Open Access | Times Cited: 9
Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study
Mingyue Cai, Wensou Huang, Wei Liang, et al.
Liver International (2024) Vol. 44, Iss. 4, pp. 920-930
Closed Access | Times Cited: 9
Therapeutic Effects of Natural Products on Liver Cancer and Their Potential Mechanisms
Jinhong Guo, Wenjie Yan, Hao Duan, et al.
Nutrients (2024) Vol. 16, Iss. 11, pp. 1642-1642
Open Access | Times Cited: 9
Evolving global etiology of hepatocellular carcinoma (HCC): Insights and trends for 2024.
Abraham Koshy
Journal of Clinical and Experimental Hepatology (2024) Vol. 15, Iss. 1, pp. 102406-102406
Closed Access | Times Cited: 9
Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial
Xiaoyang Hong, Yongjian Guo, Wenbo Shi, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Risk Factors for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Hepatocellular Carcinoma
Yuki Tsuji, Tadashi Namisaki, Hiroaki Takaya, et al.
Digestive Diseases and Sciences (2025)
Closed Access | Times Cited: 1
Newly Developed Modified ALBI Grade Shows Better Prognostic and Predictive Value for Hepatocellular Carcinoma
Masatoshi Kudo
Liver Cancer (2021) Vol. 11, Iss. 1, pp. 1-8
Open Access | Times Cited: 44
Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment
Leonardo Stella, Francesco Santopaolo, Antonio Gasbarrini, et al.
World Journal of Gastroenterology (2022) Vol. 28, Iss. 21, pp. 2251-2281
Open Access | Times Cited: 35
Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
Yujing Xin, Fei Cao, Hongcai Yang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 35
Objective Response by mRECIST to Initial Lenvatinib Therapy Is an Independent Factor Contributing to Deep Response in Hepatocellular Carcinoma Treated with Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy
Hidekatsu Kuroda, Takayoshi Oikawa, Masashi Ninomiya, et al.
Liver Cancer (2022) Vol. 11, Iss. 4, pp. 383-396
Open Access | Times Cited: 33
New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma
Masatoshi Kudo
International Journal of Clinical Oncology (2022) Vol. 27, Iss. 7, pp. 1110-1119
Open Access | Times Cited: 32

Scroll to top